LYZL1

Across TCGA pan-cancer cohorts, LYZL1 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated LYZL1 data layer compared with 6 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher LYZL1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LYZL1 expression acts as an unfavorable survival marker, although some lineages such as SKCM and PAAD show a favorable association.

ACC, SKCM, and KICH are the cancer types where LYZL1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Tertile	All	0.264	0.712	<.001	115	view →
SKCM	OS	Quartile	All	0.449	0.295	<.001	81	view →
KICH	OS	Tertile	All	0.161	0.881	<.001	72	view →
PAAD	DFS	Tertile	All	0.619	0.223	.001	30	view →
LUAD	DFS	Tertile	IV	0.342	0.893	<.001	18	view →
MESO	DFS	Tertile	All	0.500	0.223	.034	15	view →
KIRP	DFS	Quartile	All	0.548	0.807	.024	10	view →
THCA	DFS	Tertile	III,IV	0.180	0.765	.021	9	view →
LGG	DFS	Tertile	All	0.554	0.777	.010	9	view →
READ	OS	Tertile	III,IV	0.277	0.885	<.001	9	view →
LIHC	DFS	Tertile	III,IV	0.451	0.195	.033	6	view →
BRCA	OS	Tertile	IV	0.569	0.832	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

LYZL1–ACC (OS)

Open the ACC breakdown →